Cancer firm Adcendo raises EUR 51m

Danish biotech firm Adcendu secures EUR 51m from various investors including Novo Seeds. This is the largest A series investment round in the history of Danish biotech.

The Adcendo team | Photo: Bioinnovation Institute / PR

Less than one year after Adcendo selected its primary drug candidate, the Danish biotech firm has raised more than EUR 51m (USD 61.8m) in a series A financing round.

The investor syndicate is led by Novo Seeds and Ysios Capital but also includes RA Capital Management, HealthCap and Gilde Healthcare.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs